Covid news!!! 2020-07-09 15:34 ET - News Release
Mr. Paul Woodward reports
ADVANCED PROTEOME THERAPEUTICS FILES PROVISIONAL IP FOR COMPOUNDS TARGETING SARS-COV-2
Advanced Proteome Therapeutics Corp.'s United States subsidiary, Advanced Proteome Therapeutics Inc. (APTI), has filed for patent protection on a family of therapeutic candidates against SARS-CoV-2, the virus which causes COVID-19, and has initiated a project to rapidly manufacture test quantities of these drugs.
As previously announced, APTI's scientists have identified multiple compounds with predicted affinity for the SARS-CoV-2 protease exceeding that of all published candidate viral protease inhibitors known to APTI. In consultation with our patent attorneys, we believe these compounds to be novel and patentable. We have now submitted patent filings to protect these inventions.
The company has begun the process of synthesizing these candidates in-house. We expect synthesis of the first two candidates to take approximately 4 - 6 weeks. The next step will be to perform cell culture and in vivo testing in a validated SARS-CoV-2 model with an external collaborator as soon as possible, preliminary results of which would be available within 3 - 5 weeks of onset.
Dr. Benjamin Krantz, Director of APTI, commented, "This project is moving forward at a rapid pace, in line with the urgent need for better treatments for SARS-CoV-2. Multiple reports have suggested that immunity to SARS-CoV-2, secondary to vaccine or infection, may be transient, further highlighting the importance of antivirals for the treatment of COVID-19. We have now filed intellectual property around our protease inhibitor candidates and are taking the next steps of synthesizing various candidates and moving toward pre-clinical testing to confirm activity and safety."
Paul Woodward, CEO of the Company, stated, "I am extremely pleased with the ability of our Boston-based scientists to advance this program to the point of IP filing and subsequent compound synthesis in just a few weeks. While this program does not make use of our core technology, it would, if successful, be highly impactful and provide us with a near-term monetization opportunity. We look forward to the next steps."
The Company is not making any express or implied claims that its product can eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
ABOUT THE COMPANY:
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., has invented proprietary protein conjugation technology which enables the development of superior antibody-drug conjugates through improved site-specific labeling, drug-antibody ratio control and enabling of combination payloads. The technology has compelling pre-clinical data demonstrating improved homogeneity and increased in-vivo potency relative to current state of the art linker technology. The Company believes that the technology will enable the development of safer and more potent antibody-drug conjugate therapeutics and is pursuing licensing and partnership opportunities to advance development.
We seek Safe Harbor.